OphtAI (Evolucare Technologies)

Villers-Bretonneux, France  All France companies → — Founded 2019
Imaging AI Specialist Specialty-Focused AI
Bootstrapped

About OphtAI (Evolucare Technologies)

OphtAI, a solution developed by the French group Evolucare Technologies, is a healthcare AI company specializing in ophthalmology. It offers large-scale automated screening for retinal diseases using artificial intelligence. The company’s AI analyzes retinal photos from a standard field color retinograph to detect the main pathological risks to the retina, specifically focusing on Diabetic Retinopathy, Glaucoma, and Age-related Macular Degeneration (AMD). The system provides results in seconds, including photo quality assessment, severity rating, location of detected lesions, and a confidence score, all compiled into a detailed PDF report.

OphtAI’s technology aims to address the challenges faced by modern ophthalmology, such as the increasing number of patients with chronic conditions and the scarcity of specialists. By enabling non-specialists to identify patients requiring priority care, OphtAI helps reduce the workload of ophthalmologists, allowing them to focus on therapeutic management. The solution is available via a web browser (OphtAI WEB), a desktop application (OphtAI APP), or through an API for integration into partner software. It is a CE-marked Class IIA medical device and has been developed through collaborative projects with AP-HP hospitals and the Latim research laboratory, utilizing a database of 800,000 retinal images.

Focus Areas

Diabetic Retinopathy Diabetic Macular Edema Age-related Macular Degeneration Glaucoma Retinal Disease Screening Artificial Intelligence in Ophthalmology Tele-ophthalmology

Business Intelligence

TechnologyCloud-native, AI-powered image analysis, Deep Learning

What Physicians Need to Know

Specialization
OphtAI specializes in artificial intelligence (AI) tools for ophthalmology, focusing on the automated screening and detection of major retinal pathologies.
Key Pathologies Detected
Their AI algorithm can detect diabetic retinopathy (including its gradation), macular edema, glaucoma, and age-related macular degeneration (AMD) within seconds using a single color fundus image.
Accuracy & Performance
OphtAI's solution boasts high sensitivity and specificity in detecting retinal conditions, with performance comparable to, and in some cases outperforming, human experts.
Technology Stack
OphtAI offers various integration levels, including an Azure-hosted API (with on-premise installation available), URL contextual calls for browser-based access, and HTML components for displaying results.
Certifications
The OphtAI solution is a CE-marked medical device (Class IIA) and is certified by Health Canada.
Research & Development
OphtAI is the result of collaborative research with AP-HP (41 Public Hospitals) and the Latim research laboratory, drawing findings from a database of 800,000 retinas.
Physician Tip

For physicians, OphtAI offers an optimized workflow by providing automated preliminary patient sorting based on criticality and checking image quality to avoid re-examinations. The AI provides explicable results through lesion mapping and confidence indexes, helping to reduce the risk of error and identify early warning signs. It enables specialists to focus on complex cases and clinical care, while ensuring widespread and safe screening. The system can also contribute to automated patient record filling and offers customizable PDF reports. OphtAI aims to increase and expand expertise, improve productivity by delegating tasks, and facilitate multi-site organization and teleophthalmology networks.

OphtAI is designed for flexible integration into existing clinical workflows. It partners with platforms like Topcon's Harmony Referral System, a vendor-neutral data management platform, allowing access to OphtAI regardless of the color fundus device used. OphtAI's API allows for various integration levels, and it can be interfaced with most fundus cameras and ophthalmology specialty software. Specific integrations mentioned include Icare, CrystalVue, Area, Oplus, Optomed, Teo, TopCon, and UmamiView.

Products by OphtAI (Evolucare Technologies)

No products listed for this company yet. Know of one? Suggest it →

What the Web Says

OphtAI, a product of Evolucare Technologies, generally receives positive attention for its AI-powered solution in ophthalmology, particularly for diabetic retinopathy screening. While specific product reviews on major platforms like G2 or Capterra are scarce, the company is recognized for its innovative approach in healthcare technology. Employer reviews are also not readily available on Glassdoor, suggesting a smaller or less publicly reviewed company.

Overall: Positive

Strengths

  • AI-powered solution for diabetic retinopathy screening
  • Potential to improve early detection and patient outcomes
  • Innovation in ophthalmology and healthcare technology
  • Focus on a critical public health issue
  • Mentioned in healthcare IT discussions for its technological advancements

Limitations

  • Limited public product reviews on major platforms (G2, Capterra)
  • Scarcity of employer reviews on Glassdoor
  • Specific user feedback on usability and integration is not widely available
  • Potential challenges with adoption in traditional healthcare settings
  • Lack of detailed pricing or implementation information publicly available

Based on reviews from: OphtAI official website, Healthcare IT news and articles (general mentions), Evolucare Technologies information

Last updated: 2026-09-21

Videos

News, demos, and interviews about OphtAI (Evolucare Technologies).

Loading videos...

Videos load interactively. If none appear, search YouTube for OphtAI (Evolucare Technologies) →

View all on YouTube

Press & Coverage

Evolucare
OphtAI: AI for ophthalmologists
OphtAI, an AI solution for ophthalmology, is highlighted as a scientifically validated technology ready for integration into everyday practice, demonstrating high performance in detecting diabetic retinopathy, glaucoma, and AMD. The article emphasizes its role in improving early detection and optimizing medical resources, especially in resource-limited areas.
2026-03
OphtAI
OphtAI at SANTEXPO 2026: AI for visual screening
OphtAI will be exhibiting at the SANTEXPO trade fair from May 19 to 21, 2026, to present its artificial intelligence solution for screening retinal conditions. The solution analyzes retinal photos to detect major pathological risks like Diabetic Retinopathy, Glaucoma, and AMD.
2026-04
Evolucare
Evolucare OphtAI CE certified according to the MDR
OphtAI, a Class IIa medical device for automated analysis of retinal images, has obtained MDR certification, a significant milestone for the company and the ophthalmic e-health ecosystem. This certification confirms the clinical reliability, technical robustness, and regulatory compliance of the technology.
2025-12
OphtAI
AI in teleophthalmology: towards optimised eye screening
This article discusses the increasing role of AI, specifically OphtAI, in teleophthalmology for automating image analysis, securing diagnoses, and improving the efficiency of eye screening. It highlights how AI supports practitioners in decision-making and streamlines administrative tasks.
2025-10
Evolucare
OphtAI at the SFO 2025 Congress: spotlight on ophthalmological AI
OphtAI will be present at the Congress of the French Ophthalmology Society (SFO) from May 10 to 12, 2025, to showcase its artificial intelligence solution for ophthalmological screening and introduce its new MyOphtAI offering. The new offering aims to democratize access to quality AI screening with a simple, no-commitment monthly subscription.
2025-05
PubMed (Klin Monbl Augenheilkd)
Automated Diabetic Retinopathy Screening in Out-patient Diabetes Care u2013 Comparison of Two Artificial Intelligence Algorithms: RetCAD and OphtAI
A study published in Klinische Monatsblatter Fur Augenheilkunde compared OphtAI with RetCAD for automated diabetic retinopathy screening. OphtAI version 2.3.4 achieved a sensitivity of 70% and a specificity of 100% for detecting referable DR, correctly identifying all patients with severe and proliferative DR.
2025-05
ClinicalTrials.gov
OphtAI Diagnostic Performance Validation for Automated Screening of Eye Diseases
This study aims to validate the diagnostic performance of the OphtAI software for automated screening of diabetic retinopathy, diabetic macular edema, glaucoma, ARM, and AMD. Evolucare OphtAI is a medical device offering AI-powered screening capabilities.
2023-09
Topcon Healthcare
Topcon Healthcare and OphtAI Announce their Partnership in EMEA
Topcon Healthcare announced a partnership with OphtAI to integrate OphtAI's AI algorithm into Topcon's Harmony Referral System. This collaboration aims to provide eye care professionals with smarter access to AI services for detecting eye pathologies like diabetic retinopathy, macular edema, glaucoma, and AMD.
2023-02

Frequently Asked Questions

OphtAI offers an AI-powered software solution for automated screening of retinal pathologies. It is capable of detecting major retinal diseases such as diabetic retinopathy (including grading severity), diabetic macular edema, age-related macular degeneration (AMD), age-related maculopathy (early AMD), and glaucoma from fundus photographs.
OphtAI is a Class IIa medical device that has obtained MDR (Medical Device Regulation) certification in the European Union, is certified by Health Canada, and is registered under the UKCA. The solution is deployed with a certified health data hosting provider in France, complies with GDPR, and is designed to ensure security, traceability, and data protection by not storing patient-related data after processing.
OphtAI offers an unlimited, no-obligation subscription model with a 7-day free trial. It is accessible online via my.ophtai.com or through integration with existing business software, suggesting flexibility for various practice sizes and healthcare systems.
While specific details on support and implementation assistance are not extensively detailed, OphtAI aims to make AI accessible and easy to use in everyday practice. The solution can be deployed in various settings, including healthcare facilities, private practices, and teleophthalmology, and is compatible with basic infrastructure. Evolucare, the parent company, emphasizes its strong teams with functional and technical expertise to ensure smooth implementation and operations.
Yes, OphtAI has established several partnerships. Notably, it has a distribution partnership with iCare (Revenio Group Corporation) to offer OphtAI analysis in EMEA and Canada for iCare ILLUME retinal screening solutions. OphtAI was also developed in collaboration with ADCIS and is a result of a public-private R&D partnership with organizations like AP-HP hospitals and the Latim research laboratory. They also partner with Umami-Ware to promote the OphtAI solution in the German market.
OphtAI is a joint venture created by Evolucare and ADCIS, both established companies in healthcare IT and image analysis, respectively. Evolucare, founded over 35 years ago, is a leading French group in the Medical IT market with about 500 employees and 18 offices across several countries. The Evolucare Group recently joined the Italian GPI Group in mid-2023, which aims to accelerate its international deployment. OphtAI's ambition is to become an essential reference in the AI market for ophthalmology, with ongoing efforts for FDA approval to target the American market.

Related Companies

OrthoAI is a healthcare AI company that has two distinct entities. One OrthoAI, based in India, is an AI-powered surgical companion designed for orthopedic surgeons, providing evidence-based insights and decision support. It functions as a generative AI, similar to ChatGPT, specifically tailored for orthopedics, and is accessible 24/7. This platform integrates a curated database developed […]

NuvoAir is a digital health company that provides a value-based specialty care platform focused on proactive, continuous virtual care for individuals with heart and lung conditions. The company aims to transform the diagnosis and management of chronic cardiopulmonary conditions by integrating advanced monitoring technology, data analytics, and evidence-based interventions delivered by a multidisciplinary team. NuvoAir’s […]

Infinite Biomedical Technologies, LLC (IBT) is a medical device company established in 1997 with roots at Johns Hopkins University. The company is dedicated to developing innovative solutions for individuals with upper limb loss and differences, aiming to transform laboratory research into practical medical devices. IBT focuses on advanced prosthetic control systems and related technologies to […]

The search results indicate that “Strain AI” is not a single, unified company serving physicians and healthcare providers in the traditional medical sense. Instead, the term “Strain AI” appears to be a general descriptor used by several distinct companies operating primarily in the cannabis industry, leveraging AI to recommend cannabis strains based on user preferences, […]

Samsung is a global technology leader that has significantly expanded its presence in the healthcare sector, leveraging its expertise in AI, imaging, and connected devices. The company aims to improve patient care and outcomes by providing advanced diagnostic solutions, personalized health insights, and integrated digital health platforms. Samsung’s healthcare initiatives focus on bridging the gap […]

Philips (Cardiologs) is a healthcare AI company that specializes in transforming cardiac diagnostics through medical-grade artificial intelligence and cloud technology. Their core offering is the Cardiologs Holter platform, which utilizes deep neural networks to analyze continuous ambulatory ECGs. This platform is designed to streamline ECG analysis, reduce reporting errors, and accelerate diagnostic reporting, ultimately empowering […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.